Reported positive topline results from the Phase 3 VERITAC-2 trial that support global regulatory filings – – Presented first ...

Numerous studies conducted by researchers at Dana-Farber Cancer Institute report progress for cancers including head and neck cancer, metastatic breast cancer and lung cancer.

Olema Pharmaceuticals, Inc.’s OLMA share price has dipped by 5.78%, which has investors questioning if this is right time to buy.

Dr. Brian Czerniecki, of Moffitt Cancer Center, led a CURE Educated Patient® Updates in Metastatic Breast Cancer event, and ...

Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...

Essential Tools for Managing Hormone Receptor-Positive Breast Cancer Presented by Learn Look Locate and Walgreens “We know ...

Rapid breast cancer research offers new hope, as discussed by Joyce O’Shaughnessy, MD, regarding HR+/HER2– and HER2+ disease.

A growing understanding of how “reproductive” hormones sculpt the brain could transform the management of neurological ...

During a live event, Megan Kruse, MD, discussed NCCN guidelines and key therapies for patients with HR-positive metastatic ...

When treating patients with hormone-receptor positive, HER2-negative metastatic breast cancer, mutations necessitate the ...

Omission of endocrine therapy in estrogen receptor (ER)-low early breast cancer had a significant association with worse survival, particularly in patients with residual disease after neoadjuvant ...

About The Study: In this cohort study of older women with screen-detected estrogen receptor–positive or human epidermal growth factor receptor 2–negative breast cancer, prior screening ...